Tenon Medical, Inc. reported its financial results for the first quarter ended March 31, 2025, on May 13, 2025. The company recorded revenue of $0.7 million, which was in line with the first quarter of 2024.
The report highlighted the recent FDA clearance of the Catamaran® SI Joint Fusion System for a new indication to augment spinal fusion, significantly expanding its addressable market. The company also noted its robust patent portfolio, including twelve U.S. and international patents protecting its Catamaran technology.
Financially, Tenon Medical received gross proceeds of approximately $7.0 million from equity financing transactions during the period, bolstering its capital position. The company also reiterated its plan for the national commercial launch of the Catamaran SE in mid-2025, signaling upcoming product expansion.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.